Easier Biologic Access Linked to Higher Remission Rates in Severe Asthma, Global Study Finds
核心洞察
An ecological study across 21 countries found that easier biologic access (higher BACS) was very strongly correlated with achieving 2-domain (r=0.81; p<0.001) and 3-domain remission with lung function (r=0.81; p<0.001) in severe asthma (搜索).
Higher BACS was strongly associated with no exacerbations (r=0.68; p<0.001) and moderately associated with preserved lung function, well-controlled asthma, and non-use of long-term oral corticosteroids one year post-biologic initiation.
The findings suggest that earlier biologic initiation, facilitated by fewer prescription restrictions, may improve outcomes by interrupting inflammatory pathways before irreversible airway remodeling occurs.
An international study pooling data from 21 countries has demonstrated that easier access to biologic therapies is strongly associated with improved clinical outcomes in patients with severe asthma (搜索), including higher rates of on-treatment clinical remission. The findings, published in the Journal of Asthma and Allergy, represent the first real-world evidence linking biologic accessibility—measured through the Biologic Accessibility Score (BACS)—to post-biologic asthma outcomes on a global scale.
The ecological analysis drew on 9,183 patients from three major data sources: the CHRONICLE US severe asthma (搜索) registry, the International Severe Asthma Registry (ISAR), and the Optimum Patient Care Research Database (OPCRD). Researchers examined the association between country-level BACS and clinical outcomes assessed approximately one year after biologic initiation.
Remission Outcomes Show Very Strong Correlation with Access
The study found that higher BACS—reflecting fewer prescription restrictions, broader eligibility criteria, and lower administrative barriers—was very strongly correlated with achieving 2-domain remission (r=0.81; p<0.001) and 3-domain remission incorporating lung function (r=0.81; p<0.001). Strong correlations were also observed for 3-domain remission with asthma control (r=0.67; p=0.001) and 4-domain remission (r=0.71; p<0.001).
"Easier biologic access was associated with a significantly greater likelihood of achieving on-treatment clinical remission (all definitions assessed), experiencing no exacerbations, having a ppFEV1 or ppPEFR ≥80%, having well- or partly controlled asthma and having no need for LTOCS," the authors wrote.
Higher BACS was strongly correlated with the absence of exacerbations (r=0.68; p<0.001) and moderately correlated with preserved lung function (r=0.58; p=0.004), well- or partly controlled asthma (r=0.42; p=0.047), and non-use of long-term oral corticosteroids (r=0.42; p=0.045).
A Proxy for Earlier Intervention
The BACS, first described in 2021, is a composite score encompassing 10 biologic prescription criteria, each scored up to 10 points and referenced to European Medicines Agency marketing authorization specifications. Higher scores denote easier access. The authors propose that BACS may serve as a proxy for earlier biologic initiation, as countries with higher scores generally have fewer reimbursement restrictions and lower administrative hurdles, potentially allowing patients to commence biologics earlier in their disease course.
"Considering the current benchmark of biologic efficacy/effectiveness when introduced later in the disease process (eg, achievement of 3- or 4-domain remission in approximately 20–35% of patients and reduction of exacerbation rate and LTOCS both by 50%), more equitable access and timely initiation could 'move the needle' for these outcomes, unlocking the true potential of biologics," the researchers noted.
Biological Rationale and Supporting Evidence
The findings align with a growing body of evidence suggesting that earlier biologic intervention may interrupt inflammatory pathways before irreversible airway changes occur. Biologics may reduce airway hyper-responsiveness, slow accelerated lung function decline, and potentially prevent or attenuate airway remodeling. The study cites prior research showing that prolonged OCS exposure (>21 months) before biologic initiation was associated with a 71% reduced odds of achieving OCS elimination post-biologic compared to those exposed for ≤12 months.
Additionally, a recent ISAR analysis found that the odds of achieving 4-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio: 0.85; 95% CI: 0.73, 1.00), and increased by 29% for every 5% greater ppFEV1 before biologic initiation.
Patient Characteristics and Study Design
The majority of patients in the analysis were female (63.1%), of White race (79.7%), overweight or obese (72.7%), and never-smokers (65.6%). The median age at study entry was 55 years, with median asthma onset at 30 years. In the year before biologic initiation, 57.7% had experienced two or more exacerbations, 64.5% had uncontrolled asthma, and 59.2% had impaired lung function. Anti-IL-5 (搜索)/5R was the most frequently prescribed biologic class (54.0%), followed by anti-IgE (搜索) (33.8%) and anti-IL-4Rα (搜索) (12.1%).
The study employed Pearson's correlations weighted by the inverse of the variance of each estimate, with leave-one-out analyses confirming that correlations were not strongly dependent on any single setting. A sensitivity analysis using the mean BACS of the biologic actually initiated by each patient yielded similar results.
Limitations and Policy Implications
As an ecological study, the analysis was adjusted for country size but not for other potential confounders such as socioeconomic status or individual healthcare systems. The authors caution that observed associations should not be interpreted as causal and may be subject to ecological fallacy. The BACS also does not capture all accessibility issues, including cost, permitted prescribers, and time to specialist referral.
"For low-access countries, our findings highlight the need for policies that improve affordability and equitable access, such as expanding reimbursement schemes, simplifying eligibility criteria, strengthening specialist SA services, and improving access to biomarker testing and referral pathways," the authors concluded.
The study was conducted by the Observational and Pragmatic Research Institute (OPRI) and partially funded by Optimum Patient Care Global Ltd and AstraZeneca.